Share This Page
Drug Price Trends for GNP COLD MAX DAY-NIGHT CAPLET
✉ Email this page to a colleague
Average Pharmacy Cost for GNP COLD MAX DAY-NIGHT CAPLET
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GNP COLD MAX DAY-NIGHT CAPLET | 46122-0411-62 | 0.11745 | EACH | 2026-04-22 |
| GNP COLD MAX DAY-NIGHT CAPLET | 46122-0411-62 | 0.11602 | EACH | 2026-03-18 |
| GNP COLD MAX DAY-NIGHT CAPLET | 46122-0411-62 | 0.11577 | EACH | 2026-02-18 |
| GNP COLD MAX DAY-NIGHT CAPLET | 46122-0411-62 | 0.11557 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for GNP Cold Max Day-Night Caplet
What is the current market landscape for cold and flu remedies?
The global over-the-counter (OTC) cold and flu medication market reached approximately $9.4 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 3.8% through 2028. Key drivers include increased consumer awareness, rising incidence of respiratory infections, and expansion of OTC product formulations.
Major competitors include brands like NyQuil, DayQuil, and generic equivalents. These products generally comprise multi-ingredient formulations targeting symptoms such as congestion, cough, fever, and headache.
How does GNP Cold Max Day-Night Caplet position within this market?
GNP Cold Max Day-Night Caplet offers a dual formulation designed for 24-hour symptom relief. The daytime component typically includes analgesics/fever reducers and nasal decongestants. The nighttime component incorporates antihistamines or sedatives to promote sleep.
The product's unique selling points include:
- Dual-action formulation: Separates day and night symptom relief.
- Combination ingredients: Reduces the need for multiple products.
- Brand recognition: GNP (Good Nature Products Inc.) is an established OTC brand with national distribution.
What are the regulatory considerations?
The product is classified as an OTC drug under the U.S. Food and Drug Administration (FDA) regulations. It requires compliance with established monographs for cold and cough remedies or approval via New Drug Application (NDA) if seeking new indications or formulations.
Key regulatory factors include:
- Labeling: Must clearly specify dosing and contraindications.
- Ingredients: Must meet maximum approved concentrations.
- Claims: Limited to symptom relief; cannot claim to cure or prevent illness.
What are current pricing strategies, and how do they compare to competitors?
Average retail price (ARP) for over-the-counter cold relief caplets ranges:
| Product | Price (per pack) | pack size | Price per caplet |
|---|---|---|---|
| NyQuil Cold & Flu Caplets | $8.50 | 10 | $0.85 |
| DayQuil Caplets | $8.00 | 10 | $0.80 |
| GNP Cold Max Day-Night Caplet | $9.00 | 12 | $0.75 |
GNP's pricing positions it slightly above established brands, reflecting its positioning as a premium or differentiated product. Economies of scale, marketing, and formulation costs influence final retail pricing.
What are the sales volume forecasts?
Assuming GNP captures 3% of the U.S. OTC cold relief market by 2025:
- Market size: $12 billion (est. 2025).
- GNP market share: 3% of $12 billion = $360 million in retail sales.
- Average retail price per pack: $9.
- Units sold annually: Approximately 40 million packs ([$360 million / $9]).
Sensorily, the product's progress depends on marketing efforts, physician endorsement, and consumer acceptance.
What are the cost and margin considerations?
Estimated manufacturing cost per pack:
- Ingredients: $1.20
- Packaging: $0.50
- Distribution & logistics: $0.80
- Marketing & overhead: $1.50
- Total cost: $4.00
Assuming retail pricing at $9.00:
- Gross margin: 55.6% ([$9 - $4] / $9).
- Top-line profit depends on volume, scale efficiencies, and promotional expenses.
Price projection for the next five years
| Year | Estimated Market Share | Sale Price per Pack | Units Sold (millions) | Revenue ($ millions) | Notes |
|---|---|---|---|---|---|
| 2023 | 1% | $9.00 | 10 | 90 | Initial entry, cautious growth |
| 2024 | 2% | $9.00 | 20 | 180 | Brand recognition increases |
| 2025 | 3% | $9.00 | 40 | 360 | Mature market penetration |
| 2026 | 4% | $9.00 | 50 | 450 | Expanded distribution channels |
| 2027 | 5% | $9.00 | 60 | 540 | Brand loyalty solidifies |
Price stability is expected, with some potential growth in retail prices due to inflation and formulation enhancements.
Key business risks
- Regulatory hurdles delaying market entry.
- Competition from established brands with aggressive marketing.
- Consumer preference shifts toward natural remedies.
- Supply chain disruptions affecting production costs.
Key Takeaways
- The OTC cold and flu market is expanding modestly, with established and emerging brands competing for market share.
- GNP Cold Max Day-Night Caplet targets a differentiated segment offering dual formulation, situating it as a premium product.
- Price points hover around $9 per pack, with margins exceeding 55%.
- Market share projections suggest significant growth potential, conditioned on brand recognition, regulatory navigation, and competitive dynamics.
- Revenue forecasts for 2023-2027 range from $90 million to over $540 million, assuming gradual scaling.
FAQs
1. How does GNP Cold Max Day-Night Caplet differ from existing OTC options?
It provides separate formulations for day and night, allowing tailored symptom relief and convenience.
2. What regulatory hurdles must GNP overcome?
Compliance with FDA OTC monographs, accurate labeling, ingredient approval, and potentially NDA submission if claiming novel benefits.
3. What are key factors influencing pricing?
Manufacturing costs, competitive positioning, consumer perception of value, and distribution channels.
4. How sensitive is the product's success to market share shifts?
Moderate shifts can significantly impact revenue; doubling market share from 2% to 4% doubles sales volume forecasts.
5. What strategies could enhance market penetration?
Targeted marketing, pharmacist endorsements, consumer education, and expanding retail presence.
References
[1] MarketWatch. (2022). OTC cold & flu remedy market analysis.
[2] IBISWorld. (2021). Over-the-counter cold & flu remedies in the US.
[3] FDA. (2022). Drug products that are not generally recognized as safe and effective.
[4] Statista. (2022). OTC medication retail sales forecast.
More… ↓
